726 Angina pectoris stable

1 downloads 0 Views 55KB Size Report
Angina pectoris stable. P4016 | BEDSIDE. Ivabradine in combination with beta-blockers improves ejection fraction and symptom score in patients with stable ...
726

Angina pectoris stable

P4016 | BEDSIDE Ivabradine in combination with beta-blockers improves ejection fraction and symptom score in patients with stable angina pectoris and left ventricular dysfunction: 1-year follow-up of ADDITIONS study K. Werdan 1 , H. Ebelt 1 , G. Stoeckl 2 , S. Nuding 1 , F. Hoepfner 1 , U. MuellerWerdan 1 . 1 Martin Luther University of Halle-Wittenberg, Department of Cardiology, Halle, Germany; 2 Servier Deutschland GmbH, Munich, Germany Objectives: A stratified analysis of the effectiveness of ivabradine in combination with betablockers was performed for angina patients with and without left ventricular dysfunction (LVD) from the non-interventional multicenter ADDITIONS follow-up study over one year. Methods: 901 patients with chronic stable angina were treated with ivabradine bid in flexible doses in combination with betablockers for one year. Among other parameters, resting heart rate (HR), LVD, ejection fraction (EF), and severity of symptoms (CCS score) were evaluated. LVD diagnosis was based on a qualitative assessment by the physician. Descriptive statistics were performed. Results: Of 901 patients (intention to treat, mean age 65.4±10.6 years, 58% male) with chronic stable angina analyzed, 53% had undergone a PCI/CABG before and 35% had a history of myocardial infarction. All patients received betablockers (Metoprolol 41%, mean daily dose (mdd) 109.6 mg; Bisoprolol 39%, mdd 6.9 mg; Nebivolol 13%, mdd 4.9 mg; Carvedilol 7%, mdd 28.9 mg) and concomitant standard medication. Of the 901 patients, 39% (n=342) were diagnosed with LVD (+LVD) and 61% (n=559) without (-LVD). EF could be documented for 55% of all patients (n= 404). At baseline, mean HR was 85.6±12.4 bpm in the +LVD group and 86.3±12.6 bpm in the -LVD group. Overall, +LVD patients had a mean EF of 48.7±10.9% and a mean CCS grade of 2.2±0.7. Mean EF and CCS grade for -LVD patients were 61.2±11.2% and 1.7±0.7, respectively. Most patients in both groups were in CCS grade II (+LVD: 50%; -LVD: 49%) at baseline. After one year of treatment with ivabradine (mean dose 12.53±2.84 mg per day), HR reduction was comparable in the two groups (+LVD: 20.6±14.4 bpm; -LVD: 20.8±13.5 bpm). Mean EF increased by 4.5±10.6% (p